Literature DB >> 26845194

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.

Meghan Shea1, Mark S Huberman1, Daniel B Costa2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26845194      PMCID： PMC4920699          DOI： 10.1016/j.jtho.2016.01.017

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  5 in total

1.  The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

Authors:  Corey J Langer
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

2.  Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.

Authors:  Paul K Paik; Alexander Drilon; Pang-Dian Fan; Helena Yu; Natasha Rekhtman; Michelle S Ginsberg; Laetitia Borsu; Nikolaus Schultz; Michael F Berger; Charles M Rudin; Marc Ladanyi
Journal:  Cancer Discov       Date:  2015-05-13       Impact factor: 39.397

3.  Non-Small Cell Lung Cancer, Version 6.2015.

Authors:  David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Thomas J Dilling; M Chris Dobelbower; Ramaswamy Govindan; Frederic W Grannis; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Lee M Krug; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Steven E Schild; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-05       Impact factor: 11.908

4.  Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Authors:  Susan E Jorge; Sol Schulman; Jason A Freed; Paul A VanderLaan; Deepa Rangachari; Susumu S Kobayashi; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-10-31       Impact factor: 5.705

5.  Comprehensive molecular profiling of lung adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-09       Impact factor: 49.962
  5 in total
  7 in total

Review 1.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

2.  Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.

Authors:  Daniel B Costa
Journal:  Transl Lung Cancer Res       Date:  2016-06

3.  Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Authors:  Mark M Awad; Giulia C Leonardi; Sasha Kravets; Suzanne E Dahlberg; Alexander Drilon; Sinead A Noonan; D Ross Camidge; Sai-Hong I Ou; Daniel B Costa; Shirish M Gadgeel; Conor E Steuer; Patrick M Forde; Viola W Zhu; Yoko Fukuda; Jeffrey W Clark; Pasi A Jänne; Tony Mok; Lynette M Sholl; Rebecca S Heist
Journal:  Lung Cancer       Date:  2019-05-11       Impact factor: 5.705

4.  Airway stents.

Authors:  Erik Folch; Colleen Keyes
Journal:  Ann Cardiothorac Surg       Date:  2018-03

Review 5.  The multiple paths towards MET receptor addiction in cancer.

Authors:  Leslie Duplaquet; Zoulika Kherrouche; Simon Baldacci; Philippe Jamme; Alexis B Cortot; Marie-Christine Copin; David Tulasne
Journal:  Oncogene       Date:  2018-03-19       Impact factor: 9.867

6.  Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance.

Authors:  Caroline E McCoach; Trever G Bivona; Collin M Blakely; Robert C Doebele
Journal:  Clin Lung Cancer       Date:  2016-06-08       Impact factor: 4.785

7.  Responses to crizotinib and disease monitoring with circulating tumor cells in lung adenocarcinoma patient with MET exon 14 skipping mutation: A case report.

Authors:  Xiang Tan; Lei Dai; Yongyong Wang; Guanbiao Liang; Nuo Yang; Mingwu Chen
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.